Chemotherapy For Oesophago-gastric Cancer Research Articles

Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer

With clear evidence of activity for immune checkpoint inhibitors across the spectrum of solid tumour malignancies, identifying combination therapies to augment their efficacy is a high research priority. In gastro-oesophageal cancer, immune checkpoint inhibitors initially received approval for chemotherapy-refractory gastric cancer,1 then approval for second-line therapy in oesophageal squamous cancer,2,3 and more recently approval in combination with first-line chemotherapy in oesophagogastric cancer.

Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study

Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study

Relevance of MTHFR polymorphisms with response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer: a meta-analysis

ObjectiveTo evaluate the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer.DesignMeta-analysis.MethodsWe searched PubMed, Embase and Web of Science databases from inception up to...

W2074 Long-Term Consequences of Neo-Adjuvant Chemotherapy for Oesophago-Gastric Cancer On Gastric Contractility and Innervation

W2074 Long-Term Consequences of Neo-Adjuvant Chemotherapy for Oesophago-Gastric Cancer On Gastric Contractility and Innervation